960 related articles for article (PubMed ID: 28833869)
41. The EQ-5D-5L Valuation Study in Egypt.
Al Shabasy S; Abbassi M; Finch A; Roudijk B; Baines D; Farid S
Pharmacoeconomics; 2022 Apr; 40(4):433-447. PubMed ID: 34786590
[TBL] [Abstract][Full Text] [Related]
42. Estimating an EQ-5D-5L Value Set for China.
Luo N; Liu G; Li M; Guan H; Jin X; Rand-Hendriksen K
Value Health; 2017 Apr; 20(4):662-669. PubMed ID: 28408009
[TBL] [Abstract][Full Text] [Related]
43. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets.
van Hout B; Janssen MF; Feng YS; Kohlmann T; Busschbach J; Golicki D; Lloyd A; Scalone L; Kind P; Pickard AS
Value Health; 2012; 15(5):708-15. PubMed ID: 22867780
[TBL] [Abstract][Full Text] [Related]
44. Valuation of EuroQol Five-Dimensional Questionnaire, Youth Version (EQ-5D-Y) and EuroQol Five-Dimensional Questionnaire, Three-Level Version (EQ-5D-3L) Health States: The Impact of Wording and Perspective.
Kreimeier S; Oppe M; Ramos-Goñi JM; Cole A; Devlin N; Herdman M; Mulhern B; Shah KK; Stolk E; Rivero-Arias O; Greiner W
Value Health; 2018 Nov; 21(11):1291-1298. PubMed ID: 30442276
[TBL] [Abstract][Full Text] [Related]
45. Valuing health-related quality of life using a hybrid approach: Tunisian value set for the EQ-5D-3L.
Chemli J; Drira C; Felfel H; Roudijk B; Al Sayah F; Kouki M; Kooli A; Razgallah Khrouf M
Qual Life Res; 2021 May; 30(5):1445-1455. PubMed ID: 33447958
[TBL] [Abstract][Full Text] [Related]
46. A program of methodological research to arrive at the new international EQ-5D-5L valuation protocol.
Oppe M; Devlin NJ; van Hout B; Krabbe PF; de Charro F
Value Health; 2014 Jun; 17(4):445-53. PubMed ID: 24969006
[TBL] [Abstract][Full Text] [Related]
47. Dutch Tariff for the Five-Level Version of EQ-5D.
M Versteegh M; M Vermeulen K; M A A Evers S; de Wit GA; Prenger R; A Stolk E
Value Health; 2016 Jun; 19(4):343-52. PubMed ID: 27325326
[TBL] [Abstract][Full Text] [Related]
48. Valuation of the EQ-5D-5L in Taiwan.
Lin HW; Li CI; Lin FJ; Chang JY; Gau CS; Luo N; Pickard AS; Ramos Goñi JM; Tang CH; Hsu CN
PLoS One; 2018; 13(12):e0209344. PubMed ID: 30586400
[TBL] [Abstract][Full Text] [Related]
49. Interim EQ-5D-5L Value Set for Poland: First Crosswalk Value Set in Central and Eastern Europe.
Golicki D; Niewada M; Hout BV; Janssen MF; Pickard AS
Value Health Reg Issues; 2014 Sep; 4():19-23. PubMed ID: 29702801
[TBL] [Abstract][Full Text] [Related]
50. Comparing the EQ-5D-5L crosswalks and value sets for England, the Netherlands and Spain: Exploring their impact on cost-utility results.
Ben Â; Finch AP; van Dongen JM; de Wit M; van Dijk SEM; Snoek FJ; Adriaanse MC; van Tulder MW; Bosmans JE
Health Econ; 2020 May; 29(5):640-651. PubMed ID: 32059078
[TBL] [Abstract][Full Text] [Related]
51. Creating a Multiply Imputed Value Set for the EQ-5D-5L in Canada: State-Level Misspecification Terms Are Needed to Characterize Parameter Uncertainty Correctly.
Tsui TCO; Chan KKW; Xie F; Pullenayegum EM
Med Decis Making; 2024 May; 44(4):405-414. PubMed ID: 38591189
[TBL] [Abstract][Full Text] [Related]
52. An EQ-5D-5L value set for Italy using videoconferencing interviews and feasibility of a new mode of administration.
Finch AP; Meregaglia M; Ciani O; Roudijk B; Jommi C
Soc Sci Med; 2022 Jan; 292():114519. PubMed ID: 34736804
[TBL] [Abstract][Full Text] [Related]
53. Population norms of health-related quality of life in Moscow, Russia: the EQ-5D-5L-based survey.
Hołownia-Voloskova M; Tarbastaev A; Golicki D
Qual Life Res; 2021 Mar; 30(3):831-840. PubMed ID: 33237551
[TBL] [Abstract][Full Text] [Related]
54. Measuring health-related quality of life in the general population and Roma communities in Romania: study protocol for two cross-sectional studies.
Olariu E; Paveliu MS; Baican E; Oluboyede Y; Vale L; Niculescu-Aron IG
BMJ Open; 2019 Aug; 9(8):e029067. PubMed ID: 31427330
[TBL] [Abstract][Full Text] [Related]
55. EQ-5D-5L is More Responsive than EQ-5D-3L to Treatment Benefit of Cataract Surgery.
Gandhi M; Ang M; Teo K; Wong CW; Wei YC; Tan RL; Janssen MF; Luo N
Patient; 2019 Aug; 12(4):383-392. PubMed ID: 30607809
[TBL] [Abstract][Full Text] [Related]
56. Valuing EQ-5D-5L health states 'in context' using a discrete choice experiment.
Cole A; Shah K; Mulhern B; Feng Y; Devlin N
Eur J Health Econ; 2018 May; 19(4):595-605. PubMed ID: 28569351
[TBL] [Abstract][Full Text] [Related]
57. Development of an EQ-5D Value Set for India Using an Extended Design (DEVINE) Study: The Indian 5-Level Version EQ-5D Value Set.
Jyani G; Sharma A; Prinja S; Kar SS; Trivedi M; Patro BK; Goyal A; Purba FD; Finch AP; Rajsekar K; Raman S; Stolk E; Kaur M
Value Health; 2022 Jul; 25(7):1218-1226. PubMed ID: 35779943
[TBL] [Abstract][Full Text] [Related]
58. International Valuation Protocol for the EQ-5D-Y-3L.
Ramos-Goñi JM; Oppe M; Stolk E; Shah K; Kreimeier S; Rivero-Arias O; Devlin N
Pharmacoeconomics; 2020 Jul; 38(7):653-663. PubMed ID: 32297224
[TBL] [Abstract][Full Text] [Related]
59. Assessing the Use of a Feedback Module to Model EQ-5D-5L Health States Values in Hong Kong.
Wong ELY; Ramos-Goñi JM; Cheung AWL; Wong AYK; Rivero-Arias O
Patient; 2018 Apr; 11(2):235-247. PubMed ID: 29019161
[TBL] [Abstract][Full Text] [Related]
60. Comparison of online and face-to-face valuation of the EQ-5D-5L using composite time trade-off.
Jiang R; Shaw J; Mühlbacher A; Lee TA; Walton S; Kohlmann T; Norman R; Pickard AS
Qual Life Res; 2021 May; 30(5):1433-1444. PubMed ID: 33247810
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
